Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must have a confirmed and documented MS diagnosis as defined by the Revised McDonald criteria \[Ann Neurol 2005: 58:840-846\], with a relapsing-remitting disease course.~2. Subjects must be ambulatory with converted Kurtzke EDSS score of 0-5.5.~3. Subjects must be in a stable neurological condition and free of corticosteroid treatment \[intravenous (iv), intramuscular (im) and/or per os (po)\] 30 days prior to screening (month -1).~4. Subjects must have had experienced one of the following:~   * At least one documented relapse in the 12 months prior to screening~  * At least two documented relapses in the 24 months prior to screening~  * One documented relapse between 12 and 24 months prior to screening with at least one documented T1-Gd enhancing lesion in an MRI performed within 12 months prior to screening.~5. Subjects must be between 18 and 55 years of age, inclusive.~6. Subjects must have disease duration of at least 6 months (from the first symptom) prior to screening.~7. Women of child-bearing potential must practice an acceptable method of birth control \[acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy or double-barrier method (condom or diaphragm with spermicide).~8. Subjects must be able to sign and date a written informed consent prior to entering the study~9. Subjects must be willing and able to comply with the protocol requirements for the duration of the study.~Exclusion Criteria:~1. Subjects with progressive forms of MS~2. An onset of relapse, unstable neurological condition or any treatment with corticosteroids \[intravenous (iv), intramuscular (im) and/or per os (po)\] or ACTH between month -1 (screening) and 0 (baseline).~3. Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.~4. Use of immunosuppressive including Mitoxantrone (Novantrone®) or cytotoxic agents within 6 months prior to the screening visit.~5. Previous use of either of the following: natalizumab (Tysabri®), cladribine, laquinimod.~6. Previous treatment with glatiramer acetate (Copaxone®) Interferon-β (either 1a or 1b) or IVIG within 2 months prior to screening visit.~7. Systemic corticosteroid treatment of ≥30 consecutive days duration within 2 months prior to screening visit.~8. Previous total body irradiation or total lymphoid irradiation.~9. Previous stem cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.~10. A known history of tuberculosis.~11. Acute infection two weeks prior to baseline visit.~12. Major trauma or surgery two weeks prior to baseline~13. A history of vascular thrombosis (excluding catheter-site superficial venous thrombophlebitis).~14. A carrier state of factor V Leiden mutation (either homo- or heterozygous) as disclosed at screening.~15. Positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or HIV antibody as disclosed at screening visit.~16. Use of potent inhibitors of CYP3A4 within 2 weeks prior to baseline visit (1 month for fluoxetine) see detailed list in Appendix 5~17. Use of amiodarone within 2 years prior to screening visit.~18. Pregnancy or breastfeeding.~19. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical examinations, ECG, laboratory tests or chest X-ray. Such conditions may include:~    * A cardiovascular or pulmonary disorder that cannot be well-controlled by standard treatment permitted by the study protocol.~   * A gastrointestinal disorder that may affect the absorption of study medication.~   * Renal or metabolic diseases.~   * Any form of chronic liver disease, including known non-alcoholic steatohepatitis.~   * A ≥2xULN serum elevation of either of the following at screening: ALT, AST or direct bilirubin~   * A QTC interval (obtained from either 2 ECG recordings at screening or from the mean value calculated from 3 measurements at baseline visit) which is \>450msec.~   * A family history of Long- QT syndrome.~   * A history of drug and/or alcohol abuse.~   * Major psychiatric disorder.~20. A known history of sensitivity to Gd.~21. Inability to successfully undergo MRI scanning.~22. Known drug hypersensitivity that would preclude administration of laquinimod, such as hypersensitivity to: mannitol, meglumine or sodium stearyl fumarate.~Exclusion Criteria:~1. Subjects who suffer from any form of progressive MS.~2. Any condition which the investigator feels may interfere with participation in the study.~3. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation,~4. Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening~5. Previous treatment with immunomodulators within two months prior to screening~6. Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Laquinimod (Type: EXPERIMENTAL): Laquinimod 0.6 mg, oral
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).